The Menopause Digest 06/16 - 06/22

Welcome to The Menopause Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

The most important shift in perimenopause thinking right now is this: hormones don’t act in isolation. They operate inside a nervous system — and if that system is dysregulated, no amount of estradiol will fully quiet the storm.

Dr. Navaz Habib made this viscerally clear on Not Your Mother’s Menopause (Ep. 223): declining estradiol combined with low vagal tone delivers a “double hit” — amplifying systemic inflammation and driving the full symptom cascade: brain fog, sleep disruption, mood lability, joint pain, GI dysfunction. The vagus nerve, carrying roughly 80% of signals from organs to the brain, governs the cholinergic anti-inflammatory pathway. When it’s underperforming, the body stays in a low-grade inflammatory fire.

The DUTCH Podcast deepened this argument from the HPA axis direction. Unresolved trauma and chronic stress don’t just feel bad — they produce measurable, objective physiologic signatures: blunted cortisol awakening response (CAR), evening “second wind,” mismatches between free and metabolized cortisol. These patterns often validate what a patient has been trying to tell her clinician for years. Stress also quietly suppresses progesterone, disrupts ovarian signaling, and — critically — can imprint the next generation’s stress resilience.

The commercial and clinical implications are significant. Wearables tracking HRV are no longer wellness toys — they’re clinical monitoring tools. Simple, prescribable interventions (nasal diaphragmatic breathing with extended exhales, morning light exposure, consistent evening wind-down, CAR testing) can move the needle on symptom burden before or alongside hormone therapy. The strategic opportunity for practices: build a nervous system intake protocol. It costs almost nothing and delivers outsized diagnostic and therapeutic leverage.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

The second theme threading through this week’s content is that perimenopause is a whole-system metabolic event — and clinicians who treat it as a single-hormone deficiency are missing multiple leverage points.

Dr. Michelle Gordon on The Plus SideZ reframed GLP-1 plateaus as exactly what they are: predictable neuroendocrine adaptations, not medication failures. The hypothalamus defends its set point. But the insight that sharper clinicians will act on is her emphasis on menopause as a material modifier of body composition — reduced fat oxidation, increased visceral adiposity — and the emerging role of menopausal hormone therapy (MHT) as an adjunct to GLP-1 therapy, not a competitor to it. Dr. Shamita Trivedi, speaking on The Girlfriend Doctor, pushed this even further: optimize progesterone, estradiol, and thyroid first, then layer in GLP-1s. Sequence matters. Initiating anti-obesity medication in a woman with subclinical hypothyroidism and untreated perimenopause is working against your own treatment.

Menopause Mastery introduced an underappreciated structural player: the lymphatic system. The diaphragm is the primary lymph pump, and lymphatic congestion — driven by poor diaphragmatic mechanics and digestive dysfunction — can masquerade as classic perimenopausal symptoms: brain fog, edema, joint aches, belly fat accumulation. Fat-soluble hormones (estrogen, progesterone, cortisol) are carried and cleared via lymph. When that highway is congested, hormone metabolism suffers regardless of what’s being prescribed.

Dr. Shauna Watts (All About You) closed the loop on micronutrients: vitamin D and B12 deficiencies are rampant, frequently missed, and clinically indistinguishable from perimenopausal symptoms. Targeting optimal — not merely “normal” — ranges (25(OH)D of ~75–115 nmol/L; active B12 with homocysteine when borderline) is non-negotiable midlife medicine. The DXA conversation is similarly underused: baseline scanning at 50 (or earlier with risk factors) catches unexpected bone loss in women who look healthy on paper. The actionable posture for practices: build a midlife metabolic audit into the perimenopause workup — thyroid panel including free T3, vitamin D and B12 to optimal targets, body composition assessment, and a frank conversation about GLP-1s and MHT as a potential combination strategy.

The most urgent theme this week is also the most consistent: women are still being misdiagnosed, dismissed, and undertreated — and the consequences range from years of unnecessary suffering to preventable cancer deaths.

OvaryActive named the original sin directly: the 2002 WHI misinterpretation didn’t just alter prescribing habits — it created a generation of clinicians undertrained in perimenopause, and a patient population convinced that hormone therapy was dangerous. The result is a market flooded with unproven remedies and a clinical culture that defaults to “it’s normal” when a 38-year-old presents with sleep disruption, mood changes, and brain fog. The fix is structural: a brief perimenopause screen at every visit for patients aged 35–50 — sleep, vasomotor symptoms, mood, cognition, libido, bleeding. Not optional. Routine.

Rachel Zoffness, PhD, on Hit Play Not Pause (Ep. 279) brought a bracing corrective to the biomedical default: chronic pain is not a readout of tissue damage, it’s a brain-constructed experience shaped by sleep, trauma, stress, and social connection. Women are disproportionately affected, and the perimenopausal transition — with its neuroinflammatory loading — acts as an amplifier. The “pain recipe” framework she outlined is immediately deployable: map high-pain ingredients (poor sleep, stress, inactivity, toxic relationships) and systematically replace them with low-pain ones. Co-creating this with a patient in a 15-minute visit is entirely feasible and changes the therapeutic relationship.

Two episodes addressed conditions where diagnostic delay is measured in years. Dr. Jill Krapf on Sky Women’s Health (Ep. 256) laid out the lichen sclerosus/lichen planus distinction with the urgency it deserves — LS diagnosis is typically delayed ~5 years, misattributed to yeast or herpes, and left untreated long enough to cause scarring and elevate vulvar cancer risk. The protocol is clear: topical ultra-potent steroid with indefinite twice-weekly maintenance, local estrogen for GSM, and immediate biopsy when malignancy is on the differential. A topical JAK inhibitor phase 3 trial is underway — watch this space. And Dr. Barbie Taylor on Menopause Management made a pointed argument about ovarian cancer: the fallopian tube vs. ovary origin debate is a clinical distraction. There is no effective screening, mortality is high, and the WHI fallout has made clinicians too cautious about risk-reducing bilateral salpingo-oophorectomy in postmenopausal women undergoing pelvic surgery. Shared decision-making about BSO — explicit, documented, unhurried — belongs in every relevant surgical counseling encounter.

The strategic through-line across all three: the biggest clinical risk right now is not over-treatment. It’s systematic under-recognition.

URL: Listen Here

This episode reframes perimenopausal symptoms through the lens of autonomic regulation, explaining how the vagus nerve governs immune and inflammatory tone and why reduced estradiol plus low vagal tone magnify symptoms. The conversation offers practical, evidence-aligned tools—sleep protection, HRV-guided feedback, and breathing/temperature practices—to rebuild vagal tone and resilience.

• Perimenopause is a nervous system story as much as a hormone story: the vagus nerve carries ~80% afferent signals from organs to the brain and regulates inflammation via acetylcholine (the cholinergic anti-inflammatory pathway).

• Low vagal tone combined with declining estradiol creates a ‘double hit’ that amplifies systemic inflammation and drives common midlife symptoms (sleep disruption, brain fog, mood lability, joint pain, GI issues).

• Heart rate variability (HRV) on wearables is a practical proxy for autonomic balance/vagal tone; focus on trends over absolute values. Sleep quality is the strongest lever to improve HRV, while alcohol and late-night screens reliably suppress it.

• Training the vagus nerve is possible: nasal, diaphragmatic breathing with longer exhales, temperature therapy (cold/heat), brief breath-holds, and movement all build autonomic resilience when used safely.

• A sense of safety (physiologic, psychological, biochemical) is required for vagal activation; chronic stress, trauma, poor metabolic health, and environmental stressors keep the ‘accelerator’ on and wear out the ‘brakes.’

For midlife women, systematically restoring vagal tone and autonomic regulation—monitored by HRV and anchored in sleep-first care—can downshift systemic inflammation across organ systems and markedly reduce perimenopausal symptom burden, complementing hormone management.

Prescribe a daily 5–10 minute nasal, diaphragmatic breathing routine with longer exhales (e.g., inhale 4 seconds through the nose, exhale 6–8 seconds through the nose), performed 2–3 times per day and at bedtime; track HRV trends on a wearable to gauge response.

URL: Listen Here

This episode explores how chronic and early-life stress shape women’s hormones and health, and how clinicians can use nuanced HPA-axis assessment (e.g., CAR, free vs. metabolized cortisol, cortisone balance/clearance) to translate physiology into therapeutic plans. It outlines a trauma-informed, staged method (physical, emotional, relational/soul) to restore nervous-system regulation and, in turn, hormonal balance. Limitations: several studies were discussed conceptually without full citations in the audio.

• Chronic stress and unresolved trauma are tightly linked to women’s hormonal dysregulation across the lifespan (fertility, perimenopause, menopause); mind and body must be addressed together.

• HPA-axis patterns (e.g., blunted cortisol awakening response with evening ‘second wind,’ mismatches between free vs. metabolized cortisol, and cortisol–cortisone balance/clearance) provide an objective physiologic “story” that often validates patients’ lived experience even when stress is not consciously perceived.

• Stress can reduce progesterone’s availability/effect (impacting sleep, anxiety, ovulation) and alter ovarian and brain signaling; early-life and prenatal stress can imprint offspring HPA-axis function and later stress resilience.

• Clinicians should create trauma-informed, spacious encounters—many women have never been asked about stress/trauma; unexpressed emotions (e.g., resentment) may correlate with inflammation and somatic findings (e.g., cysts/fibroids).

• A staged, whole-person approach (HER Method)—physical support (tracking/testing, sleep, detox/methylation, nutrition), emotional work (discernment, boundaries, somatic therapies), and relational/soul alignment—can recalibrate the nervous system and produce more durable hormone balance.

Integrating trauma-informed history with objective stress physiology (particularly the cortisol awakening response, free vs. metabolized cortisol, cortisol–cortisone balance, and clearance on DUTCH Plus) is often the key to effective, lasting hormone care—because nervous-system dysregulation commonly drives the hormonal symptom pattern.

Add cortisol awakening response (CAR) testing for women with perimenopausal symptoms, cycle irregularity, fertility issues, insomnia, or ‘wired-and-tired’ patterns, and pair results with a simple daily protocol: morning light/exposure and brief movement within 30–60 minutes of waking to restore CAR, plus a consistent evening wind‑down (dim light, screens off, breathwork) to lower late-day cortisol; re-test to personalize further (e.g., address cortisol–cortisone imbalance or rapid clearance).

URL: Listen Here

This bonus episode introduces the authors’ evidence-based, patient-centered approach to perimenopause and previews their audiobook, emphasizing validation, clear distinctions between perimenopause and menopause, and the wide variability of symptoms. It underscores gaps in clinician training, the fallout from WHI misinterpretation, and the need to replace dismissal and unproven “cures” with informed, individualized care; as an introductory excerpt, it outlines scope rather than detailed protocols.

• Perimenopause is distinct from menopause; it can begin in the late 30s or early 40s (even early 30s), often with more pronounced and variable symptoms despite ongoing menses.

• Common perimenopausal symptoms include sleep disruption, hot flashes, mood changes, cognitive complaints (brain fog), libido changes, weight gain, skin/hair changes, irregular or heavy bleeding, and even joint pain.

• Women’s perimenopausal concerns are frequently minimized or dismissed; validating symptoms and encouraging open dialogue are essential to care.

• Many clinicians receive limited formal training in perimenopause, and misinterpretation of the WHI study fueled fear of hormone therapy and a market of unproven or unsafe remedies; evidence-based, individualized treatment is available.

• Midlife hormonal transition carries longer-term health implications (e.g., osteoporosis and cardiovascular disease), warranting anticipatory guidance and risk mitigation.

Recognize and proactively address perimenopause—even when periods continue—by validating patients’ experiences and offering evidence-based, individualized management (including hormone therapy when appropriate) rather than dismissing symptoms as “normal.”

Add a brief perimenopause screen to visits for patients aged 35–50: ask about sleep, vasomotor symptoms, mood/anxiety, cognition, libido, weight changes, and bleeding patterns; provide education and discuss evidence-based options or refer to a Menopause Society–certified practitioner when needed.

URL: Listen Here

This episode explains why GLP-1–treated patients commonly encounter weight-loss plateaus: the brain defends a set point via hunger and energy-expenditure adaptations, while GLP-1s primarily lower appetite and food reward. The hosts and Dr. Gordon outline safe, practical responses—maintain therapy, avoid very-low-calorie diets, emphasize fiber/protein and resistance training—and highlight menopause as a key modifier where MHT may reduce visceral fat. Limitations: the discussion is conversational and some cited studies were referenced generally without formal bibliographic details.

• Body weight is tightly regulated by hypothalamic neuroendocrine circuits (a defended “set point”); weight loss triggers increased hunger signaling, changes in satiety (including leptin dynamics), and reduced energy expenditure, which promote regain.

• GLP-1 receptor agonists reduce hunger and food reward and can lower the defended weight, but weight-loss plateaus are expected as intake slowly rises and expenditure falls; a plateau does not mean the medication stopped working.

• Very-low-calorie diets are unsafe and counterproductive; target gradual loss (about 1–2 lb/week), prioritize dietary fiber and adequate protein, and incorporate resistance training to preserve muscle and support longevity and cognition.

• Menopause/perimenopause materially shift body composition (reduced fat oxidation and more visceral fat); menopausal hormone therapy can reduce visceral adiposity and may be an important adjunct for midlife women alongside anti-obesity medications.

• Obesity is a chronic, relapsing disease; discontinuing effective therapy (e.g., tirzepatide) leads to substantial weight regain (about two-thirds in SURMOUNT-4), so long-term, individualized, multi-modal care (medications, nutrition, activity, sleep/stress care) is required.

Weight-loss stalls on GLP-1 therapy are neuroendocrine adaptations—not medication failure—and optimal management is continued pharmacotherapy combined with lifestyle measures and, for many midlife women, evaluation for and potential use of menopausal hormone therapy to address visceral adiposity.

During a GLP-1 plateau, do not stop the medication; instead, reassess and set a concrete plan: add 25–30 g/day of dietary fiber (produce plus psyllium as needed), ensure ~1.0–1.2 g/kg/day protein, begin resistance training 2–3 days/week, and in midlife women screen for peri/menopause and discuss MHT when appropriate.

URL: Listen Here

Pain psychologist Rachel Zoffness, PhD, explains why pain is a brain‑constructed, biopsychosocial experience and how central sensitization underlies chronic pain. She outlines practical tools—‘pain recipe’ mapping, graded activity pacing, sleep hygiene, social medicine, trauma‑informed care, and CBT—that clinicians can combine with biomedical treatments to improve outcomes for women in perimenopause/menopause and beyond.

• Pain is not a direct readout of tissue damage; it is constructed by the brain using biopsychosocial inputs. Emotions and pain share neural circuitry (e.g., limbic system, amygdala), which is why stress and mood can amplify or dampen pain.

• Women are disproportionately affected by chronic pain. Prior trauma and hypervigilance can turn the nervous system into a pain ‘megaphone,’ and these factors can also intensify perimenopausal/menopausal symptoms; treating trauma can meaningfully reduce pain.

• Adopt the ‘pain recipe’ model: identify high‑pain ingredients (e.g., poor sleep, high stress, inactivity, ultra‑processed diet, toxic relationships, excessive screen time) and replace them with low‑pain ingredients (sleep hygiene, movement, sunlight, social connection, boundaries, nourishing diet).

• For chronic pain, graded movement (pacing) is foundational to down‑regulate central sensitization. Start below the symptom threshold and progress slowly; sunlight, social engagement, and distraction during flares also help lower pain signaling.

• Pills and procedures can be necessary but are rarely sufficient. Long‑term opioids risk opioid‑induced hyperalgesia; evidence‑based behavioral care (CBT for chronic pain/insomnia), social medicine, and education about central sensitization improve function and pain.

Chronic pain is best understood and treated as a disease of central sensitization within a biopsychosocial framework; assessing and addressing modifiable factors—sleep, stress/trauma, activity, and social connection—can substantially reduce pain and improve function, especially in women during midlife hormonal transitions.

In your next visit with a chronic pain patient, co-create a one‑page ‘pain recipe’ (high‑ vs low‑pain ingredients), then prescribe a graded activity pacing plan that starts below the flare threshold, pair it with brief sleep‑hygiene counseling, and schedule a 4‑week follow‑up to track functional goals (time out of bed, minutes walking) rather than pain scores alone.

URL: Listen Here

This episode examines the evolving role of testosterone therapy for women—what the evidence supports (libido), how dosing and delivery differ across settings and countries, and why careful monitoring and informed consent matter amid regulatory gaps in the U.S. It also touches on rapidly advancing longevity science, from cellular rejuvenation to GLP-1 medicines, underscoring both new opportunities and the need for rigorous study in women’s health.

• At physiologic doses targeting late-30s female levels, testosterone shows a modest, placebo-adjusted benefit primarily for low libido; consistent improvements in energy, muscle, or bone have not been demonstrated in the best data (e.g., Australian studies), and benefits may take ~3 months to appear.

• There is no FDA-approved testosterone product for women in the U.S.; current options include off-label use of male gels (dividing a tube over ~10 days), compounded creams, or pellets—pellets and supraphysiologic dosing are unpredictable and carry higher risk.

• High or poorly monitored dosing can cause virilizing effects (hirsutism, acne, clitoromegaly, voice deepening), mood/anger changes, and hair loss; testosterone can aromatize to estrogen, raising theoretical concerns for estrogen-receptor–positive breast cancer, and long-term safety data are limited.

• Clinicians who prescribe typically obtain baseline labs and monitor levels to keep dosing within physiologic female ranges; informed consent about risks, side effects, and the lack of long-term outcomes is essential. Telehealth platforms may offer access, but patients should understand prescribing, monitoring, and dispensing relationships.

• The conversation situates testosterone within a broader longevity landscape, including emerging cellular rejuvenation research and GLP-1 medicines that may affect weight, cravings, alcohol intake, and potentially population longevity—illustrating rapid change alongside evidence gaps.

For peri/postmenopausal women with hypoactive sexual desire, a carefully monitored, physiologic-dose transdermal testosterone trial can improve libido, but clinicians should avoid pellets/supraphysiologic dosing, counsel on virilizing and mood side effects, and monitor levels given aromatization to estrogen and uncertain long-term safety.

For a patient with persistent low libido after addressing other contributors, offer a 3–6 month trial of low-dose transdermal testosterone (off-label male gel divided to achieve physiologic female levels), with baseline and 6–12 week follow-up testosterone (and clinical) monitoring, clear counseling on side effects, and avoidance of pellets/high-dose regimens.

URL: Listen Here

This episode reframes common perimenopausal/menopausal complaints through the lens of lymphatic health, emphasizing the diaphragm’s role as the core lymph pump and the gut‑lymph axis as a frequent upstream driver of symptoms. Practical, low‑risk tools—maximum inspiratory nasal breathing, postprandial walking, gentle yoga/twists, and dry brushing—are paired with an Ayurvedic‑informed, evidence‑aligned approach to restore lymph flow and digestion before or alongside hormone therapy.

• The lymphatic system is a key, often overlooked driver of perimenopausal and menopausal symptoms—carrying immune cells, clearing cellular waste, and delivering/clearing fat‑soluble hormones (estrogen, progesterone, testosterone, cortisol); congestion presents as edema, brain fog, skin rashes, joint aches, and visceral/belly fat.

• The diaphragm is the primary lymphatic pump; maximum inspiratory nasal breathing that fully contracts/relaxes the diaphragm can reduce GERD, lower blood pressure, enhance glymphatic (brain waste) clearance during sleep, and improve energy and cognition.

• Digestive dysfunction (insufficient stomach acid, bile flow, pancreatic enzymes, impaired parasympathetic tone) is an upstream cause of lymph congestion; poorly digested proteins/fats and fat‑soluble pollutants divert into gut lymph (GALT), promoting belly fat and systemic symptoms.

• Simple movement and fascia support improve lymph flow: 15 minutes of postprandial walking (preferably nasal breathing) lowers post‑meal glucose and cardiovascular strain; gentle yoga/twists with diaphragmatic breathing and dry brushing/raw‑silk ‘garshana’ stimulate lymph and interstitial fascia drainage.

• Before defaulting to restrictive diets, chronic digestive enzymes, or immediate hormone therapy, screen for lymph and digestive issues and address them with breathing/movement, diet (berries/greens, hydration), and targeted Ayurvedic strategies; lymph support can also relieve PMS/perimenopausal symptom clusters.

Many symptoms attributed solely to perimenopause/menopause hormones may stem from lymphatic dysfunction driven by impaired diaphragmatic mechanics and digestion; restoring diaphragmatic function and gut‑lymph flow can reduce symptom burden and optimize hormone metabolism and response to therapy.

Initiate a 2–4 week trial for symptomatic patients: teach a 5‑minute maximum inspiratory nasal‑breathing routine (three‑part breath with full exhalation; 10 reps reaching up, 10 left, 10 right) once–twice daily and prescribe a 15‑minute nasal‑breathing walk after lunch and dinner; track reflux, edema, brain fog, blood pressure, and waist circumference.

URL: Listen Here

This episode advocates an integrative, personalized endocrine approach to women’s midlife care—optimizing thyroid and sex steroids first, then selectively layering therapies such as GLP‑1s within a structured program. The discussion highlights nuanced use of bioidentical hormones (including progesterone post‑hysterectomy), individualized thyroid replacement (often T4+T3), and careful GLP‑1 initiation/tapering to reduce side effects and weight regain.

• Integrative endocrinology emphasizes individualized, head-to-toe hormone care—identify the common thread tying symptoms together rather than treating isolated complaints.

• Premature ovarian insufficiency and early menopause require both physiologic and psychological support; birth control pills can be a short-term bridge but cycling bioidentical estrogen and progesterone is often preferred when ready.

• Perimenopause/menopause management should “layer” therapies: prioritize bioidentical progesterone for sleep/brain benefits, add estradiol/testosterone as indicated, and avoid high, unopposed estrogen; even without a uterus, progesterone remains clinically valuable.

• GLP-1 receptor agonists can reduce appetite, improve insulin sensitivity and inflammation, but work best after optimizing sex steroids and thyroid; use a structured, monitored program (start low/slow, track body composition, pair with nutrition and resistance training, and taper slowly to minimize rebound).

• Thyroid care should target optimal—not merely “normal”—ranges; assess TSH, free T4, free T3 (± antibodies) and consider combined T4+T3 therapy, as subclinical hypothyroidism and low-normal free T3 can be highly symptomatic.

In midlife women with weight redistribution, cognitive/sleep changes, and metabolic shifts, optimize progesterone, estradiol/testosterone, and thyroid function (often with combined T4+T3 to patient-specific targets) before initiating GLP‑1 therapy; this sequencing improves tolerance, preserves lean mass, and enhances outcomes.

For symptomatic peri/postmenopausal patients with “normal” basic thyroid tests, order TSH, free T4, free T3, and thyroid antibodies; treat toward patient-specific optimal targets (e.g., TSH ~0.5–2.0 and free T3 in the upper half of normal), consider combined T4+T3 if free T3 is low-normal with symptoms, and add nighttime bioidentical progesterone to improve sleep and cognition.

URL: Listen Here

This episode clarifies that “fungal acne” is Malassezia folliculitis and explains how to distinguish it from acne by clinical features and triggers. It outlines effective OTC and prescription antifungal approaches, supportive keratolytics, and lifestyle strategies for both clearance and maintenance—highly relevant for managing acneiform eruptions that fail conventional acne therapy.

• “Fungal acne” is Malassezia (yeast) folliculitis, not true acne; it presents as small, monomorphic, often itchy papules that occur in clusters—commonly on the forehead/hairline and chin—and typically lacks comedones (blackheads/whiteheads).

• Risk factors include oily skin, heat/humidity and sweating (athletes, hot climates), tight/occlusive clothing, recent antibiotic use (microbiome disruption), and immunocompromise; acne and Malassezia folliculitis can coexist.

• Conventional acne treatments often fail; first-line OTC options are antifungal washes/shampoos (ketoconazole 1% [Nizoral], selenium sulfide [Selsun Blue], zinc pyrithione) used as a face/body wash and left on for several minutes before rinsing.

• Adjuncts that benefit both acne and Malassezia folliculitis include sulfur cleansers/masks and salicylic acid (BHA) cleansers/peels; niacinamide can help calm skin and reduce oil.

• Maintenance and prevention: use antifungal/keratolytic washes 1–2x weekly, avoid oily/occlusive leave-on products (oils, tallow, slugging), change out of sweaty clothes promptly and cleanse or use hypochlorous acid; seek dermatology care for refractory cases or for prescription-strength antifungals.

In patients with an acneiform eruption that is pruritic, monomorphic, clustered, and devoid of comedones—especially in oily, sweaty, or humid conditions—suspect Malassezia folliculitis and prioritize antifungal therapy over standard antibacterial/acne regimens.

When Malassezia folliculitis is suspected, start a topical antifungal wash regimen (e.g., ketoconazole shampoo 1–2% or zinc pyrithione wash) applied to affected areas and left on 3–5 minutes daily for 1–2 weeks, then reduce to twice weekly for maintenance; counsel patients to minimize occlusion (oily products/tight gear) and to change out of sweaty clothing promptly.

URL: Listen Here

This episode outlines how to clinically distinguish lichen sclerosus from lichen planus, emphasizes the need for biopsy and microscopy when appropriate, and details steroid-based regimens with long-term maintenance plus hormone therapy to optimize outcomes. It also covers management of erosive LP/DIV, strategies for addressing scarring and sexual function, and highlights an ongoing phase 3 trial of a topical JAK inhibitor that could transform LS care.

• Differentiate lichen sclerosus (LS) from lichen planus (LP) clinically: LS favors vulvar skin (inner labia majora, labia minora, clitoral hood, perineum, perianal) with hypopigmentation, thickening, and pruritus; LP preferentially involves the vestibule and can extend into the vagina with erosions, rawness, and Wickham striae—true vaginal involvement is rare in LS.

• Diagnosis is often delayed (∼5 years for LS) and misattributed to yeast or herpes; biopsy when diagnosis is uncertain, when overlapping conditions are suspected, or if malignancy is a concern (consider a ~2‑week steroid washout if feasible), and use microscopy to identify DIV (elevated pH, leukocytes, parabasal cells, reduced lactobacilli) that commonly accompanies erosive LP.

• First-line therapy for both LS and LP is topical corticosteroids, but regimens must be individualized with clear dosing and an indefinite maintenance phase (often twice weekly) to prevent flares, scarring, and reduce vulvar cancer risk; steroids reduce inflammation but do not reverse existing scarring or correct hypoestrogenic tissue.

• Address genitourinary syndrome of menopause (GSM) in parallel: apply local estrogen (and, when appropriate, DHEA/prasterone or compounded low-dose testosterone) to the vagina, vestibule, and external vulva to restore tissue health; for erosive vestibular LP, prefer tacrolimus (or pimecrolimus) over ultra‑potent steroids to avoid vestibular thinning.

• Functional impairment (clitoral phimosis, introitus stenosis) requires a stepwise approach—disease remission, hormonal optimization, pelvic floor/scar mobilization—with procedural/surgical release when symptomatic; lasers remain experimental for LS. A multicenter phase 3 trial of a topical JAK inhibitor for LS is underway, reflecting a targeted, user-friendly future beyond steroids.

LS and LP are chronic autoimmune dermatoses that demand accurate clinical distinction and lifelong, maintenance anti-inflammatory therapy—paired with local hormone restoration—to prevent scarring and reduce vulvar cancer risk; recognizing vestibule/vaginal disease and DIV strongly points to LP and changes management.

Adopt a standardized LS protocol: prescribe an ultra‑potent topical steroid ointment to active areas once daily, taper to every other day, then to twice‑weekly indefinite maintenance; provide a vulvar application map with explicit instructions, add local estrogen to the vestibule/vulva/vagina when hypoestrogenic, schedule reassessment in 6–12 weeks, and biopsy immediately if diagnosis is uncertain or malignancy is suspected.

URL: Listen Here

This episode outlines how vitamin D and B12 deficiencies frequently mimic perimenopausal symptoms and are often overlooked. It provides practical targets and treatment strategies—D3 with magnesium (and possibly K2), evidence-based thresholds for testing/retesting, when to use B12 injections, and why earlier DXA screening can catch unexpected bone loss in otherwise healthy, active women.

• Vitamin D deficiency is common even in sunny climates due to indoor living and sun protection; higher-risk groups include people with darker skin, obesity, indoor workers, and children. Aim for an optimal 25(OH)D of ~75–115 nmol/L (not just “within range” at ~50).

• Use vitamin D3 (preferred over D2) at ~1,000–2,000 IU daily; consider adding magnesium to aid activation/utilization and K2 to help direct calcium to bone (avoid K2 in patients on vitamin K–antagonist anticoagulants). Routine calcium supplementation is unnecessary if serum calcium is adequate.

• Bone health planning should start earlier: consider a baseline DXA around age 50 (earlier with early menopause or strong family history) and repeat every two years if low; combine with weight-bearing exercise and vitamin D optimization.

• B12 deficiency often presents with nonspecific fatigue and neuropathic symptoms (e.g., tingling); risks include vegan/vegetarian diets, malabsorption (celiac disease, pernicious anemia), alcohol use, and PPIs. Evaluate with total B12 and, if equivocal, add active B12 and homocysteine.

• Treat severe B12 deficiency (<~185 pmol/L) with intramuscular B12 (e.g., three injections over three weeks); recheck after 3–4 months. Consider methylated B12 (methylcobalamin) especially if MTHFR variants are suspected; sprays are a reasonable alternative to tablets.

In midlife women with perimenopausal symptoms (fatigue, brain fog, low mood, poor sleep), do not assume hormones are the sole cause—vitamin D and B12 deficiencies are common, frequently missed, and require testing and treatment to optimal (not merely ‘normal’) targets to protect bone, mood, and neurologic health.

For midlife patients with non-specific symptoms, routinely order 25(OH)D and B12; if B12 is borderline, add active B12 and homocysteine. Treat vitamin D to ~75–115 nmol/L with daily D3 (1,000–2,000 IU) plus magnesium (consider K2 if not on vitamin K–antagonist anticoagulants), use IM B12 for clear deficiency, and consider a baseline DXA around age 50 (earlier with risk factors).

URL: Listen Here

This episode contends that arguing whether serous epithelial ovarian cancer arises in the fallopian tube or ovary is a distracting detail that should not change prevention and management priorities. Dr. Taylor links fear-driven shifts after the WHI report to current reluctance toward risk-reducing salpingo-oophorectomy in postmenopausal women, urging clinicians to keep focus on high mortality, absent screening, and practical risk reduction.

• Serous epithelial ovarian cancer (the postmenopausal concern) involves the serous lining common to both ovary and fallopian tube; given their anatomic continuity and rapid peritoneal spread, pinpointing the exact site of origin offers little clinical advantage.

• Debate over whether cancer starts in the fallopian tube versus the ovary should not distract from the core realities: there is no effective screening, early detection is uncommon, and mortality is high.

• The episode argues that fallout from the 2002 WHI hormone therapy report fostered fear-based practice changes that, in turn, reduced use of estrogen therapy and shifted gynecologic surgical standards away from aggressive risk-reducing removal of postmenopausal ovaries/tubes.

• Current tendencies to conserve ovaries during benign gynecologic surgeries in postmenopausal women are criticized as misaligned with the lethality and detectability profile of serous epithelial ovarian cancer.

• Clinicians and patients should prioritize big-picture risk reduction and avoid letting single-study details derail sound prevention and management strategies.

For postmenopausal patients, management should center on the high lethality and lack of reliable screening for serous epithelial ovarian cancer; the ovary-versus–fallopian tube origin debate should not meaningfully alter risk assessment, vigilance for any postmenopausal ovarian enlargement, or counseling about risk-reducing bilateral salpingo-oophorectomy when appropriate.

During counseling for postmenopausal patients undergoing pelvic surgery or evaluation of an adnexal mass, explicitly discuss the disease’s poor detectability and prognosis and include shared decision-making about risk-reducing bilateral salpingo-oophorectomy, rather than allowing the site-of-origin debate to drive management choices.

URL: Listen Here

This episode outlines how to maintain weight after anti-obesity medications by treating obesity as a chronic, relapsing disease that requires long-term, individualized strategies. Practical guidance includes medication titration based on appetite cues, protein- and fiber-forward, low–energy-density eating patterns (with optional meal replacements), hydration, and higher-dose physical activity, alongside early, stigma-free follow-up and family support.

• Obesity is a chronic, relapsing disease; post–weight loss biology (increased hunger signals, reduced satiety, and lowered resting energy expenditure) promotes weight regain.

• Anti-obesity medications often need to be continued long term; doses should be individualized and titrated to hunger/satiety, side effects, cardiometabolic risks, and life stressors—avoid dose reductions during high-risk periods (e.g., holidays).

• When medications are reduced or stopped, emphasize nutrition for satiety and preservation of lean mass: prioritize protein (~1.0–1.2 g/kg/day) spread across meals, increase fiber and low–energy-density foods, limit ultra-processed foods, consider one daily meal replacement, use structured meal patterns, self-monitor intake/weight, and maintain hydration.

• Physical activity is pivotal for weight maintenance (less so for weight loss): target 200–300 minutes/week of moderate–vigorous activity plus regular resistance training, using shared decision-making to match patient preferences.

• Set expectations for maintenance from the first visit: normalize setbacks, address stigma/shame, encourage early follow-up at first signs of regain, involve family/supports, and review other medications that may contribute to weight gain.

Manage obesity like other chronic conditions (e.g., hypertension or hypothyroidism): sustained, proactive maintenance—including ongoing pharmacotherapy titrated to appetite and risk factors plus structured nutrition and activity—is usually required to counter physiology favoring weight regain.

At goal weight or when tapering anti-obesity medication, schedule a dedicated maintenance visit to (1) assess hunger/satiety and adjust medication dose accordingly, (2) prescribe ~1.0 g/kg/day of protein divided across meals with added fiber and a daily high-protein meal replacement if helpful, (3) set an activity target of 200–300 minutes/week plus 2–3 weekly resistance sessions, and (4) arrange close follow-up around high-risk periods (e.g., holidays, major stress).

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.

👉Discover the Menopause Premium Program